Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China

NCT07593248 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT07593248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07593248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
June 22, 2026
Completion date
June 30, 2031
Enrollment
2,000 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer